AnalysisNews

APMD today

$17.80+$1.52 (+9.34%)close Nov 17, 2026

Trend

DailyDowntrend (confirmed)

4 hourStrong Bullish

1 hourStrong Bullish

15 minStrong Bullish

5 minSymmetric Triangle

Daily trend turns up above $19.57

Key levels

Resistance$24.50

Resistance$19.57

Support$16.43

Support$13.88

Latest news & SEC filings

EarningsApnimed Posts Q3 2026 Results, Gives Business Update

EarningsApnimed posts quarterly loss of $1.05 per share, revenue $2.480M

SEC FilingApnimed, Inc. filed a report on a major company event (Form 8-K)

All APMD news →

Nasdaq · Healthcare

Apnimed, Inc. (APMD)

$17.80+1.52 (+9.34%)
BUYGrade: B+Risk: MEDIUM
1D5D1M1Y5YMaxSign up for all timeframes
15.2316.2917.3618.4217.80Oct 15Oct 23Nov 2Nov 10
High17.89
Low15.86
Open16.03
Volume382K
Avg Vol370K
VWAP17.19
30d High19.49
30d Low14.16
30d Chg-1.33%

What Is the Price Target for APMD?

SEPT Low Target

$41.00

SEPT Mid Target

$50.00

SEPT High Target

$60.00

Analyst Consensus

$50.00

Current: $16.28Upside: +207.1%Confidence: 65%Method: Analyst Consensus

Is APMD a Buy or Sell Right Now?

73
Investability Score
BUY12-18 months
News summary · last 30 days
Nov 16▲ UpEarnings3 articles
Apnimed (APMD) reported Q3 2026 results, posting a quarterly loss of $1.05 per share that was wider than the $0.59 loss analysts had projected, while revenue fell to $2.480 million from $8.802 million a year earlier. The company also filed a Form 8-K disclosing a major corporate event alongside its business update. Despite the bearish earnings miss, the stock closed up 1.81% at $16.34, trading in a wide range between $15.80 and $17.10 on volume of 226,892 shares. The positive close suggests investors may be looking past the weak quarter toward the operational developments highlighted in the business update, though the sharply lower revenue and wider loss remain a cautionary signal.

Thesis

    Test your own strategy on APMD

    Describe your strategy in plain words, then scan, alert, backtest and paper trade it on APMD with SEPT’s own market data.

    Start Free Trial →

    Is APMD Overvalued or Undervalued?

    Valuation Verdict

    UNDERVALUED

    Methods Used

    Analyst Consensus

    Fair Value

    $50.00

    0

    Moat Score

    NONE

    0/9

    Piotroski Score

    N/A

    Altman Z-Score

    What Is Smart Money Doing with APMD?

    Insider Signal

    NEUTRAL

    0 buys / 0 sells (90d)

    Congress Signal

    NEUTRAL

    0 buys / 0 sells (90d)

    Institutional

    N/A

    Short Squeeze Risk

    MEDIUM

    Signal: NEUTRAL

    Track Smart Money Across 4,000+ Stocks

    Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

    See Smart Money Data →

    APMD Growth Story

    Revenue YoY

    N/A%

    3yr Revenue CAGR

    N/A%

    EPS Growth YoY

    N/A

    FCF Growth YoY

    N/A%

    Revenue Trend

    UNKNOWN

    Dark Pool Trades for APMD

    PREVIEW

    Recent off-exchange (dark pool) prints for APMD: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.

    TimePriceSizeValueSide
    16:43:08$17.442,866$$50KBUY
    15:56:50$16.791,061$$18KSELL
    15:27:08$16.881,473$$25KBUY
    15:21:10$16.842,000$$34KBUY
    15:18:45$16.851,000$$17KBUY

    5 dark pool trades shown · $$143K preview volume

    Real-time institutional flow, block trades, and net positioning

    See all dark pool activity

    Full AI Research Report

    SEPT's Trading AI has generated a free, downloadable PDF research report for Apnimed, Inc. (APMD) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

    Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...

    Your strategy, tested before real money.

    Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.

    Try SEPT Free for 7 Days →

    APMD — frequently asked questions

    What is APMD stock price today?

    Apnimed, Inc. (APMD) is at $17.80, up 9.34% (+$1.52) at the Nov 17, 2026 close.

    Why is APMD stock up today?

    Nov 16, 2026: Apnimed (APMD) reported Q3 2026 results, posting a quarterly loss of $1.05 per share that was wider than the $0.59 loss analysts had projected, while revenue fell to $2.480 million from $8.802 million a year earlier. The company also filed a Form 8-K disclosing a major corporate event alongside its business update.

    What is the APMD price target?

    The average analyst price target for APMD is $50.00, ranging from $41 to $60, based on 3 analysts. Latest: LifeSci Capital initiates on Aug 25, 2026.

    What do analysts rate APMD?

    Analyst ratings for APMD: 4 Buy, 0 Hold, 0 Sell — consensus Strong Buy.

    Did APMD beat earnings?

    APMD last reported on Nov 16, 2026: EPS -$1.05 vs -$0.59 expected — a miss of 78.0%.

    What are APMD support and resistance levels?

    Support: $16.43, $13.88. Resistance: $19.57, $24.50, $30.22.

    What are insiders doing with APMD?

    Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.

    What is the latest news on APMD?

    Nov 16, 2026: Apnimed Posts Q3 2026 Results, Gives Business Update · Nov 16, 2026: Apnimed posts quarterly loss of $1.05 per share, revenue $2.480M · Nov 16, 2026: Apnimed, Inc. filed a report on a major company event (Form 8-K)